 Patch one is part of a signaling pathway called the hedgehog signaling pathway, which in and of itself has got kind of a interesting background. It's very important developmentally. It's not that important in adults except for tumor formation. It's really well known to be a driver mutation for basal cell carcinoma, but most BCC basal cell can just be surgically removed, excised. It's a skin cancer. Well, what we found is roughly two and a half percent of all cancer patients have that as a driver mutation and it comes across all different types of cancer. So that's 40,000 patients a year just in the United States. I think in colorectal, it's roughly 8% of all patients. Inometrial, it's around 6%. So when we found that data, we brought in a drug from Lilly that was best in class based on over 200 patients that they had tested in nearly all basal cell, but they decided not to develop just because basal cell is a relatively small market. They didn't think of what we did. There's a lot of other patients, 40,000 patients potentially a year that could really benefit from this drug.